-
Mashup Score: 0Biosimilars Month in Review: December 2023 - 11 month(s) ago
The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 0Aflibercept Biosimilar SB15 Demonstrates Comparable Efficacy, Safety - 11 month(s) ago
Efficacy, pharmacokinetics, immunogenicity, and safety were comparable between patients receiving the aflibercept biosimilar SB15 and the reference drug.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Efficacy, pharmacokinetics, immunogenicity, and safety were comparable between patients receiving the #aflibercept #biosimilar SB15 and the reference drug. https://t.co/Cu5Uxoq0zB
-
-
Mashup Score: 0Study Examines Factors Impacting Health-Related Quality of Life in Male Patients with Gout - 11 month(s) ago
Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with gout.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Various factors related to demographics, psychosocial behavior variables, and clinical characteristics were linked to health-related quality of life in patients with #gout. https://t.co/wOEayt0tgF
-
-
Mashup Score: 3Fasting Plasma Glucose Linked to Myocardial Dysfunction in Gout - 11 month(s) ago
Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Findings provide a theoretical framework for the early diagnosis and treatment of #HeartDisease in patients with #gout, especially for older individuals and those with hypertension. https://t.co/RGbacq82Kh
-
-
Mashup Score: 1Maternal Study Satisfaction Increases Visit Compliance in Children at Risk for Diabetes - 11 month(s) ago
Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 diabetes.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 #diabetes. https://t.co/R7BEUixVrW
-
-
Mashup Score: 1Stacie Bell, PhD: Adverse Childhood Experiences in Pediatric SLE - 11 month(s) ago
Stacie Bell, PhD, highlights the lasting effects of childhood adversities in patients with pediatric lupus.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Stacie Bell, PhD, highlights the lasting effects of childhood adversities in patients with pediatric #lupus. https://t.co/igXmWg8STO
-
-
Mashup Score: 4Micki Hultquist, MS: Long-term Anifrolumab-fnia Data Demonstrate Safety, Efficacy in SLE - 11 month(s) ago
Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials. https://t.co/INX8360KAI #Lupus #Rheumatology
-
-
Mashup Score: 4Micki Hultquist, MS: Long-term Anifrolumab-fnia Data Demonstrate Safety, Efficacy in SLE - 11 month(s) ago
Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Data from the phase 3 TULIP long-term extension trial support the favorable benefit-risk profile of anifrolumab-fnia demonstrated in previous trials. https://t.co/INX8360KAI #Lupus #Rheumatology
-
-
Mashup Score: 1Maternal Study Satisfaction Increases Visit Compliance in Children at Risk for Diabetes - 11 month(s) ago
Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 diabetes.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Maternal characteristics, sociodemographic factors, and paternal participation during the initial year of the TEDDY study were identified as key predictors of enhanced visit compliance in a pediatric cohort genetically predisposed to type 1 #diabetes. https://t.co/R7BEUixVrW
-
-
Mashup Score: 2Fasting Plasma Glucose Linked to Myocardial Dysfunction in Gout - 11 month(s) ago
Findings provide a theoretical framework for the early diagnosis and treatment of heart disease in patients with gout, especially for older individuals and those with hypertension.
Source: www.hcplive.comCategories: General Medicine News, RheumatologyTweet-
Findings provide a theoretical framework for the early diagnosis and treatment of #HeartDisease in patients with #gout, especially for older individuals and those with hypertension. https://t.co/RGbacq82Kh
-
The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased #biosimilars uptake in the US, a recent FDA approval, and the impact of a mandatory switch to an adalimumab #biosimilar in New Zealand. https://t.co/BkVW654YDP